Safello Announces IPO Plans in First Half of 2021
News provided by
Share this article
Share this article
Swedish fintech startup Safello has raised SEK 11 million in a new share issue and aims for listing on the Nasdaq First North Growth Market in 2021.
STOCKHOLM, Dec. 18, 2020 /PRNewswire/
Safello is a Stockholm-based fintech startup that offers a transparent and user-friendly exchange platform for cryptocurrencies with 165,000 customers and more than SEK 800 million in transaction volume.
Safello reached profitability in mid-2019 and has had an increased order growth of 831%. In recent months, the company has introduced several new products and services, including Safello Business, broadening its offering from private individuals to corporate clients.
Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules
Nanoform
Inside information
December 17, 2020 at 7:15 p.m. Finnish time
Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules
Helsinki, Finland – Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc, an innovative drug development company, today announced that they have signed a letter of intent to collaborate to seek to enhance nasal drug delivery to the brain of Herantis’ CDNF and xCDNF therapies (Parkinson’s disease) using Nanoform’s proprietary biological nanoparticle technology.
Gofore Oyj: Invitation to Gofore s virtual Capital Markets Day on 14 January 2021
Invitation to Gofore s virtual Capital Markets Day on 14 January 2021
Gofore invites analysts, investors and media representatives to its virtual Capital Markets Day on 14 January 2021 from 12:00 to 16:00 EET.
Capital Markets Day focuses on Gofore s updated strategy, growth plans and business outlook. The management presentations will enlarge on the strategic and financial objectives and the plans to achieve them.
In addition to CEO Mikael Nylund, the speakers of the day are Teppo Talvinko (CFO), Kristiina Härkönen (Chief Sustainability Director), Juha Virtanen (Director, Sales and Customer Value), Elja Kirjavainen (Director, Digital Transformation), Aki Koikkalainen (Director, Digital Services Development) and Miika Nurminen (Director, Digital Quality Assurance).
(1)
STOCKHOLM, Dec. 16, 2020 /PRNewswire/
Diamyd Medical and the Critical Path Institute (C-Path) are proud to announce their collaboration to significantly improve the scientific community s insight into type 1 diabetes (T1D) through Diamyd Medical s contribution of fully anonymized data from a European Phase III trial to the Trial Outcome Measures Initiative (TOMI) T1D integrated database.
The Phase III trial evaluated the use of the diabetes vaccine Diamyd
, an antigen-specific immunotherapy based on the auto-antigen GAD (glutamic acid decarboxylase), to induce immunological tolerance and stop the autoimmune destruction of insulin producing cells. The Data Contribution Agreement between Diamyd Medical and C-Path will allow for this unique set of fully anonymized clinical trial data to be integrated into an ever-growing list of committed trial data sets within the TOMI-T1D project.
OncoZenge expands the board with Hilde Furberg
Search jobs OncoZenge expands the board with Hilde Furberg
OncoZenge AB (publ) (“OncoZenge”), Moberg Pharma AB (publ)’s subsidiary, has at an Extraordinary Shareholders Meeting today resolved on expanding the board with Hilde Furberg ahead of the listing on Nasdaq First North Growth Market, which is planned to take place during the first quarter of 2021.
Hilde Furberg (born 1958) represents Linc AB and is an independent consultant and a professional board member. She has broad senior leadership experience, coming from her over 35 years in sales, marketing, strategy and general management roles in pharmaceuticals and biotechnology. Her experience is in different areas of specialty care, and from small to large global companies. Hilde has worked in companies like Baxter and Genzyme, and she was most recently the European Head of Rare Diseases for Sanofi Genzyme. Hilde has also been a board member of Pr